European Medicines Agency issues guidance on AI use in pharma regulatory science
Osborne Clarke Variability in results, potential "hallucinations" (that is, inaccurate responses, as defined in the EMA guidance) and data securityrisksare among …
Read the original at Osborne Clarke ↗
- Topics
- Regulation & PolicyHealthcareGovernment & Public SectorHallucinations & Fabrication
- Mentions
- Europe
- Tags
- AI Use Case
- Tracked via
- Google Alert “AI Risks”